MENU
CANC
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

CANC stock forecast, quote, news & analysis

The investment seeks to provide long-term growth... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
CANC
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for CANC with price predictions
Oct 22, 2026

CANC in +4.90% Uptrend, advancing for three consecutive days on October 20, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CANC advanced for three days, in 172 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on CANC as a result. In 47 of 54 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

The Moving Average Convergence Divergence (MACD) for CANC just turned positive on October 20, 2026. Looking at past instances where CANC's MACD turned positive, the stock continued to rise in 23 of 28 cases over the following month. The odds of a continued upward trend are 82%.

CANC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

CANC moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CANC crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

The Aroon Indicator for CANC entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb Co (NYSE:BMY), Moderna (NASDAQ:MRNA), Guardant Health (NASDAQ:GH), Exelixis (NASDAQ:EXEL).

Industry description

The investment seeks to provide long-term growth. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Oncology ETF (CANC) ETF is 66.17B. The market cap for tickers in the group ranges from 420.54M to 1.13T. LLY holds the highest valuation in this group at 1.13T. The lowest valued company is AUTL at 420.54M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Oncology ETF (CANC) ETF was 2%. For the same ETF, the average monthly price growth was -3%, and the average quarterly price growth was 8%. TNGX experienced the highest price growth at 23%, while IBRX experienced the biggest fall at -17%.

Volume

The average weekly volume growth across all stocks in the Tema Oncology ETF (CANC) ETF was 12%. For the same stocks of the ETF, the average monthly volume growth was 21% and the average quarterly volume growth was 8%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 44
Price Growth Rating: 46
SMR Rating: 80
Profit Risk Rating: 74
Seasonality Score: 14 (-100 ... +100)
CANC in +4.90% Uptrend, advancing for three consecutive days on October 20, 2026